The Number Everyone Will Quote About European Launches Rests on Eleven Products
The 22.9% figure driving coverage of European launch delays is 48 products falling to 37. The pricing finding underneath it is stronger and barely quoted.
The Brief
Singapore Approved Both Blenrep Combinations. Korea Reimbursed Only the One With Survival Data.
Same drug, same week, two Asian markets. The regulator approved on progression-free survival. The payer funded only the regimen with overall survival data.
A KAIST Barrier Chip Separated Three Glioblastoma Patients That MGMT Testing Called Identical
Three glioblastoma patients returned identical MGMT results and behaved differently on a barrier chip. The sample size is three, and the framing still matters.
Two FDA Device Authorisations, Two Sets of Evidence Narrower Than the Headline
Aletta matches human phlebotomists only when it agrees to attempt a draw. Narwhal cleared on bench and animal data, citing a trial with a different probe.
Two First-Ever Rare Disease Approvals Landed the Same Day. Both Were Measured by Proxy.
Pasatru’s flare benefit is clinician-assessed only. GENGLYCOS is indicated to reduce cornstarch intake. Two firsts, both measured a step from the patient.
A UC Irvine Team Names Five Mitochondrial Drug Classes for CAR-T Neurotoxicity and Says Nobody Is Testing Any of Them
Five mitochondrial drug classes named for CAR-T neurotoxicity, and the authors say none is under formal investigation. Every one is generic or preclinical.
Everyone’s New Pharma Lane Runs Through Heathrow
Two carriers built new pharma lanes in five weeks. Both end at Heathrow, an airport that lost a day to one transformer fire in March 2025.
MHRA Puts Microbiome Medicines Inside the Existing Framework While the EU Builds a Separate One
No bespoke regime is coming. Microbiome medicines meet the standard biological bar in the UK, while the EU builds a separate SoHO framework.
PDUFA VIII Keeps Every Review Clock and Hires Four Auditors
Industry renegotiated what it pays FDA without changing what it gets. The clocks held. What expanded is the apparatus for verifying the money buys reviewers.
The First Phase 3 Win for an mRNA Cancer Therapy Arrives Without Its Numbers
The first Phase 3 win for an mRNA cancer therapy. Statistical significance was reported, effect size was not, and overall survival is still open.